Eiko Lifesciences Share Price
46.00-0.53 (-1.14%)
-11.57% past 1 Year
Eiko Lifesciences Limited is carrying the business of an investment company and for that purpose to invest in, acquire, sell, transfer, subscribe for, hold and otherwise deal in and invest
Corporate filings & documents
Announcements
The Company has sent a letter providing the weblink and QR Code for accessing the Notice convening the 49th Annual General Meeting ("AGM") and the Annual Report of the Company for the Financial Year 2025-26 to the following categories of shareholders:i. Shareholders who have not registered their email addresses with the Company its Registrar and Share Transfer Agent ("RTA") or the Depository Participants ("DPs");ii. Shareholders who have registered their email addresses with the Company its RTA or the DPs but to whom the Notice could not be delivered on account of an invalid email address;iii. Shareholders who have registered their email addresses with the Company its RTA or the DPs but in whose case the intimation email regarding the AGM has bounced back and the Notice could therefore not be delivered; andiv. Shareholders holding equity shares of the Company in physical form.
1 week agoThe Company has sent a letter providing the weblink and QR Code for accessing the Notice convening the 49th Annual General Meeting ("AGM") and the Annual Report of the Company for the Financial Year 2025-26 to the following categories of shareholders:i. Shareholders who have not registered their email addresses with the Company its Registrar and Share Transfer Agent ("RTA") or the Depository Participants ("DPs");ii. Shareholders who have registered their email addresses with the Company its RTA or the DPs but to whom the Notice could not be delivered on account of an invalid email address;iii. Shareholders who have registered their email addresses with the Company its RTA or the DPs but in whose case the intimation email regarding the AGM has bounced back and the Notice could therefore not be delivered; andiv. Shareholders holding equity shares of the Company in physical form.
1 week agoNewspaper Advertisement for 49th Annual General Meeting (AGM) of the Company scheduled to be held on Tuesday 22nd day of September 2026 at 04:00 P.M. IST through Video Conference / Other Audio-Visual Means
1 week agoNewspaper Advertisement for 49th Annual General Meeting (AGM) of the Company scheduled to be held on Tuesday 22nd day of September 2026 at 04:00 P.M. IST through Video Conference / Other Audio-Visual Means
1 week agoPursuant to provision of Regulations 30 and 34 of the SEBI LODR Regulations 2015 we wish to inform that the 49th Annual General Meeting of the Company will be held on Tuesday 22nd day of September 2026 at 04:00 P.M. (IST) through Video Conferencing/ Other Audio Visual Means. Please find enclosed the copy of the Annual Report of 49th AGM for the Financial Year 2025-26 of the Company. The 49th Annual Report is also being uploaded on the website of the Company at www.eikolifesciences.com. In compliance with the SEBI circulars the Annual Report along with the Notice of the AGM is being sent only by electronic mode to those shareholders whose e-mail addresses are registered with the Company/ Registrar and Transfer Agent of the Company/Depository Participants. For those shareholders who have not registered their email ids a letter providing a weblink from where the Notice of the AGM and Annual Report for the financial year 2025-26 can be accessed is being sent.
1 week agoPursuant to provision of Regulations 30 and 34 of the SEBI LODR Regulations 2015 we wish to inform that the 49th Annual General Meeting of the Company will be held on Tuesday 22nd day of September 2026 at 04:00 P.M. (IST) through Video Conferencing/ Other Audio Visual Means. Please find enclosed the copy of the Annual Report of 49th AGM for the Financial Year 2025-26 of the Company. The 49th Annual Report is also being uploaded on the website of the Company at www.eikolifesciences.com. In compliance with the SEBI circulars the Annual Report along with the Notice of the AGM is being sent only by electronic mode to those shareholders whose e-mail addresses are registered with the Company/ Registrar and Transfer Agent of the Company/Depository Participants. For those shareholders who have not registered their email ids a letter providing a weblink from where the Notice of the AGM and Annual Report for the financial year 2025-26 can be accessed is being sent.
1 week agoPursuant to provision of Regulations 30 and 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform that the 49th Annual General Meeting of the Company will be held on Tuesday 22nd day of September 2026 at 04:00 P.M. (IST) through Video Conferencing/ Other Audio Visual Means (VC/ OAVM).Please find enclosed the copy of the Notice of 49th AGM for the Financial Year 2025-26 of the Company. The Notice of the 49th AGM is also being uploaded on the website of the Company at www.eikolifesciences.com and on website of our RTA M/s. Bigshare Services Private Limited at www.ivote.bigshareonline.com.
1 week agoPursuant to provision of Regulations 30 and 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform that the 49th Annual General Meeting of the Company will be held on Tuesday 22nd day of September 2026 at 04:00 P.M. (IST) through Video Conferencing/ Other Audio Visual Means (VC/ OAVM).Please find enclosed the copy of the Notice of 49th AGM for the Financial Year 2025-26 of the Company. The Notice of the 49th AGM is also being uploaded on the website of the Company at www.eikolifesciences.com and on website of our RTA M/s. Bigshare Services Private Limited at www.ivote.bigshareonline.com.
1 week agoThe Meeting of the Board of Directors of the Company held today i.e. on Monday 24th August 2026 Board inter-alia considered the following:1. Noting of resignation of Ms. Hasti Doshi (DIN: 10757758) from the position of Independent Director with effect from closing of business hours of 24th August 2026 due to other career commitments.
1 week agoThe Meeting of the Board of Directors of the Company held today i.e. on Monday 24th August 2026 Board inter-alia considered the following:1. Noting of resignation of Ms. Hasti Doshi (DIN: 10757758) from the position of Independent Director with effect from closing of business hours of 24th August 2026 due to other career commitments.
1 week agoAppointment of Mr. Suraj Mahadev Gaikwad (DIN: 11159369) as Additional Director (Independent and Non-Executive) of the Company to hold the office up to the date of the ensuing Annual General Meeting of the Company and thereafter as an Independent Director of the Company for a term of 5 (five) years subject to the approval of shareholders.
1 week agoAppointment of Mr. Suraj Mahadev Gaikwad (DIN: 11159369) as Additional Director (Independent and Non-Executive) of the Company to hold the office up to the date of the ensuing Annual General Meeting of the Company and thereafter as an Independent Director of the Company for a term of 5 (five) years subject to the approval of shareholders.
1 week agoMeeting of the Board of Directors of the Company held today i.e. on Monday 24th August 2026 Board inter-alia considered the following:1. Noting of resignation of Ms. Hasti Doshi from the position of Independent Director.2. Approved appointment of Mr. Suraj Mahadev Gaikwad as Additional Director (Independent and Non-Executive) of the Company.3. Recommendation of Re-appointment of Mr. Bhavesh Dhirajlal Tanna (DIN: 03353445) as a Director liable to retire by rotation who has offered himself for re- appointment.4. Convening AGM for the Financial Year 2025-26. The AGM will be held on Tuesday 22nd September 2026 at 04:00 PM via Video Conferencing/Other Audio-Visual Means.5. Approved Notice of 49th Annual General Meeting of the Members of the Company.6. Appointed Mr. Shravan Gupta (ACS: 27484 CP: 9990) as the Scrutinizer.7. Appointment of M/s Bigshare Services Pvt Ltd. as the service provider for conducting the e-voting and video conferencing for the upcoming AGM.
1 week agoMeeting of the Board of Directors of the Company held today i.e. on Monday 24th August 2026 Board inter-alia considered the following:1. Noting of resignation of Ms. Hasti Doshi from the position of Independent Director.2. Approved appointment of Mr. Suraj Mahadev Gaikwad as Additional Director (Independent and Non-Executive) of the Company.3. Recommendation of Re-appointment of Mr. Bhavesh Dhirajlal Tanna (DIN: 03353445) as a Director liable to retire by rotation who has offered himself for re- appointment.4. Convening AGM for the Financial Year 2025-26. The AGM will be held on Tuesday 22nd September 2026 at 04:00 PM via Video Conferencing/Other Audio-Visual Means.5. Approved Notice of 49th Annual General Meeting of the Members of the Company.6. Appointed Mr. Shravan Gupta (ACS: 27484 CP: 9990) as the Scrutinizer.7. Appointment of M/s Bigshare Services Pvt Ltd. as the service provider for conducting the e-voting and video conferencing for the upcoming AGM.
1 week agoAs per PDF attached.
2 weeks agoAs per PDF attached.
2 weeks agoDisclosure of Conversion of 305000 Warrants into Equity Shares belonging to Promoter and Non Promoter Category
2 weeks agoDisclosure of Conversion of 305000 Warrants into Equity Shares belonging to Promoter and Non Promoter Category
2 weeks agoPursuant to Regulations 30 and 47 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015 The copy of newspaper publication in the following newspapers dated 13th August 2026 with respect to Unaudited Financial Results (Standalone & Consolidated) of the Company for the Quarter ended 30th June 2026 approved at the meeting of Board of Directors held on Wednesday 12th August 2026 is attached herewith. 1. Financial Express (English)2. Mumbai Lakshadeep (Marathi)
3 weeks agoPursuant to Regulations 30 and 47 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015 The copy of newspaper publication in the following newspapers dated 13th August 2026 with respect to Unaudited Financial Results (Standalone & Consolidated) of the Company for the Quarter ended 30th June 2026 approved at the meeting of Board of Directors held on Wednesday 12th August 2026 is attached herewith. 1. Financial Express (English)2. Mumbai Lakshadeep (Marathi)
3 weeks agoPursuant to the Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) and amendments thereto this is to inform that the Meeting of the Board of Directors of the Company held today i.e. on Wednesday 12th August 2026 which commenced at 1:00 PM and concluded at 01:40 PM Board inter-alia approved and taken on record the following:1. Approved Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th June 2026 along with Limited Review Report issued by the Statutory Auditors of the Company.
3 weeks agoPursuant to the Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) and amendments thereto this is to inform that the Meeting of the Board of Directors of the Company held today i.e. on Wednesday 12th August 2026 which commenced at 1:00 PM and concluded at 01:40 PM Board inter-alia approved and taken on record the following:1. Approved Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th June 2026 along with Limited Review Report issued by the Statutory Auditors of the Company.
3 weeks agoEiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 inter alia to consider and approve The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended on 30th June 2026 in accordance with Regulation 33 of the SEBI Listing Regulation
3 weeks agoEiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 inter alia to consider and approve The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended on 30th June 2026 in accordance with Regulation 33 of the SEBI Listing Regulation
3 weeks agoCertificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 30th June 2026
1 month agoCertificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 30th June 2026
1 month agoTrading Window shall remain closed for designated persons and their immediate relatives from Wednesday 01st July 2026 till 48 hours after the date of Board Meeting wherein inter-alia the approval of Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th June 2026 would be considered by the Board.
2 months agoTrading Window shall remain closed for designated persons and their immediate relatives from Wednesday 01st July 2026 till 48 hours after the date of Board Meeting wherein inter-alia the approval of Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th June 2026 would be considered by the Board.
2 months agoNewspaper publication dated 27th May 2026 for Audited Financial Results (Standalone & Consolidated) of the Company for the Quarter and Year ended 31st March 2026 approved by the Board at their meeting held on 26th May 2026.
3 months agoRe-appointment of M/s NP Rajput & Co as Internal Auditor for FY 2026-27 at the Board Meeting held on 26th May 2026.
3 months agoRe-appointment of M/s NP Rajput & Co as Internal Auditor for FY 2026-27 at the Board Meeting held on 26th May 2026.
3 months agoAudited Financial Results (Standalone and Consolidated) for quarter and year ended 31st March 2026
3 months agoAudited Financial Results (Standalone and Consolidated) for quarter and year ended 31st March 2026
3 months agoAnnual Secretarial Compliance Report for the year ended on 31st March 2026.
3 months agoAnnual Secretarial Compliance Report for the year ended on 31st March 2026.
3 months agoEiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2026 inter alia to consider and approve The Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ending on 31st March 2026 in accordance with Regulation 33 of the SEBI ListingRegulation.
3 months agoIn view of SEBI circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated 26th November 2018 and amendments thereto (the said Circular) we wish to inform you that as on 31st March 2026 Eiko Lifesciences Ltd. is not a Large Corporate in terms of the criteria specified under the said SEBI Circular. In view of this the framework for fund raising by issuance of Debt Securities by Large Corporate is not applicable to Eiko Lifesciences Ltd. and the requirement of filing the initial disclosure and annual disclosure does not arise.
4 months agoCertificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter and year ended on 31st March 2026 received from M/s. Bigshare Services Pvt. Ltd. Registrar and Share Transfer Agent of the Company.
4 months agoCertificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter and year ended on 31st March 2026 received from M/s. Bigshare Services Pvt. Ltd. Registrar and Share Transfer Agent of the Company.
4 months agoPursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015 as amended and as per Companys Code of Conduct for Regulating Monitoring and Reporting of Trading by Insiders (Code) the trading window for dealing in the securities of the Company shall remain closed for designated persons and their immediate relatives from Wednesday 01st April 2026 till 48 hours after the date of Board Meeting wherein inter-alia the approval of Audited Standalone and Consolidated Financial Results for the quarter and year ended 31st March 2026 would be considered by the Board.
5 months agoThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Bhavesh Dhirajlal Tanna
6 months agoThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Bhavesh Dhirajlal Tanna
6 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Lenus Finvest Pvt Ltd
6 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Lenus Finvest Pvt Ltd
6 months agoAllotment of 6 25 000 Equity Shares and 29 50 000 Warrants on preferential basis under SEBI (ICDR) Regulations 2018 through Circulation on Tuesday 24th February 2026
6 months agoAllotment of 6 25 000 Equity Shares and 29 50 000 Warrants on preferential basis under SEBI (ICDR) Regulations 2018 through Circulation on Tuesday 24th February 2026
6 months agoNewspaper publication of Un-audited Financial results (standalone & Consolidated) for Quarter and Nine- Months ended on 31st December 2025.
7 months agoPursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) and amendments thereto this is to inform that the Meeting of the Board of Directors of the Company held today i.e. on Thursday 29th January 2026 Board inter-alia considered and approved Unaudited Financial Results (Standalone & Consolidated basis) for the Quarter ended 31st December 2025. The Statutory Auditors have carried out a Limited Review of the Unaudited Financial Results for the Quarter ended 31st December 2025. Further Pursuant to the Regulation 33 of the Listing Regulations we are enclosing herewith a copy of the Unaudited Financial Results and Limited Review Report of the Statutory Auditors of the Company. The Meeting was commenced at 12: 30 PM and concluded at 13:00 PM.
7 months agoEiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/01/2026 inter alia to consider and approve Unaudited standalone and consolidated FInancial results for quarter ended 31st December 2025
7 months agoCertificate under Regulation. 74(5) of SEBI DP Act 2018 for the Quarter ended 31st December 2025.
7 months agoAnnual reports
Concalls & investor presentations
May 2023
ConcallPresentation
Jul 2021
ConcallPresentation
Apr 2021
ConcallPresentation
Feb 2021
ConcallPresentation
Corporate Actions
Date
Type
Details
2023-07-07
Rights
2:3;45.0
Company details
Registered office
604, Centrum, Opp. T M C Office Near Satkar Grande Hotel Wagle Wagle Thane Maharashtra PIN: 400604 Tel No: 022 25390009 / 9082668855 Fax No: NULL Email: [email protected] Internet: www.eikolifesciences.com
Registrars
Office No S6-2, 6th Floor, Pinnacle Business Park,ext to Ahura Centre, Mahakali Caves Road, Andheri (East) Mumbai - 400093(old address - Bharat Tin Works building, 1st floor, Opp. Vasant Oasis, Andheri East Mumbai - 400 059Tel: + 91 21 626 38200Fax: Office No S6-2, 6th Floor, Pinnacle Business Park Next to Ahura Centre, Mahakali Caves Road Andheri (E) PIN: Tel No: 91-022-62638200 Fax No: 91-022-62638299 Email: [email protected]
Management
Chintan Doshi, Company Secretary & Compliance Officer
Laxmikant Ramprasad Kabra, Chairman
Bhavesh Dhirajlal Tanna, Non Independent & Non Executive Director
Rajkumar Govindas Baheti, Non Executive Independent Director
Kajal Dhanpatraj Kothari, Non Executive Independent Director
Hasti Doshi, Non Executive Independent Director
Sumukh Vartak, Whole Time Director
Details
BSE 540204
NSE NULL
ISIN INE666Q01016